When cardiomyopathy, cancer, and COVID-19 collide: A case report.

Autor: Symonds L; Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA., Natarajan P; Division of Cardiology, University of Washington School of Medicine, Seattle, WA, USA., Cheng RK; Division of Cardiology, University of Washington School of Medicine, Seattle, WA, USA., Lam DL; Department of Radiology, University of Washington School of Medicine, Seattle, WA, USA., Kilgore M; Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA., Kim J; Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, USA., Calhoun K; Department of Surgery, University of Washington School of Medicine, Seattle, WA, USA., Minami E; Division of Cardiology, University of Washington School of Medicine, Seattle, WA, USA., Gralow JR; Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA, USA.
Jazyk: angličtina
Zdroj: The breast journal [Breast J] 2021 Apr; Vol. 27 (4), pp. 384-386. Date of Electronic Publication: 2021 Feb 01.
DOI: 10.1111/tbj.14182
Abstrakt: Malignancy has historically prohibited solid organ transplant; however, patients with effectively treated, favorable-risk cancers should not necessarily be eliminated as transplant candidates. These cases require careful review by a multidisciplinary team. Here, we report the case of a woman with end-stage heart failure undergoing heart transplant evaluation during the COVID pandemic who was found to have early-stage, hormone receptor-positive breast cancer. Given her favorable cancer-related prognosis, a multidisciplinary committee recommended lumpectomy, accelerated partial breast irradiation, and adjuvant aromatase inhibitor therapy for definitive treatment to allow for consideration of orthotopic heart transplant.
(© 2021 The Authors. The Breast Journal published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje